FDA Updates Sentinel Initiative Status - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Updates Sentinel Initiative Status


ePT--the Electronic Newsletter of Pharmaceutical Technology

In a presentation published on FDA’s website on March 15, 2012, Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research, outlined the current status and future plans for FDA’s Sentinel Initiative, an electronic drug-safety tracking system established as part of the FDA Amendments Act of 2007.

Woodcock’s presentation outlined Mini-Sentinel, a pilot project developed to inform and facilitate development of the Sentinel System for monitoring the safety of FDA-regulated medical products. Collaborators in Mini-Sentinel include data and academic partners that provide access to healthcare data and ongoing scientific, technical, methodological, and organizational expertise.

Mini-Sentinel includes a coordinating center that can access automated healthcare data systems to develop and evaluation scientific methodologies that might be used in the fully operational Sentinel System. The pilot program would also provide FDA with the opportunity to investigate safety issues in existing data systems.

The presentation also featured an update on other plans in development, including a framework to refine safety signals in “near real time” and plans to incorporate registries and other data sources to match nonpersonally identifiable data.

Also featured in the presentation was the Observational Medical Outcomes Partnership (OMOP) project, which includes an active surveillance community and a research experiment to test various methods for detecting associations between drugs and medical outcomes and characterizing datasets and investigation of the impact of multiple “parameter settings” for each method.

Future plans for the Sentinel Initiative include expansion of data sources through Mini-Sentinel, continued research, and ongoing data utilization. FDA envisions a public-private partnership that would “allow other parties to participate in research and studies using Sentinel infrastructure.” FDA also hopes for a future national secondary use data resource for research, according to the presentation.

The Sentinel Initiative was established to create a postmarket risk identification and analysis system to link and analyze safety data from multiple sources, including federal health-related electronic data and private-sector electronic health data. By linking the data, FDA hopes to identify and evaluate safety issues “in near real time.” The Initiative will also give FDA access to longer-term data and expand access to advents not normally reported to FDA.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here